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Abstract Stress urinary incontinence is not a deadly disease, but for the large population of
women suffering from it, it is a very important issue. Especially in the continuously aging pop-
ulation all over the world, there is more and more need for treatment of this serious medical
condition. Treatment of female stress urinary incontinence exists already for ages. In the 20th
century invasive treatments like Burch colposuspension and pubovaginal slings were the main-
stay of surgical treatments. The introduction of the midurethral sling made the procedure less
invasive and accessible for more caregivers. Luckily there are many options available and the
field is developing quickly. In recent years many new medical devices have been developed,
that increase the number of treatment options available and make it possible to find a suitable
solution for the individual patient based on subjective and objective results and the chances of
complications. This manuscript provides an introduction to the therapeutical options that are
available nowadays for female stress urinary incontinence.
ª 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Stress urinary incontinence (SUI) is defined as “the invol-
untary loss of urine on effort or physical exertion or on
sneezing or coughing” [1]. It is a common medical condition
with a severe impact on quality of life. Symptoms of urinary
incontinence are prevalent in 25% of the female population
above 20 years [2], 50% of which are stress incontinence
symptoms. The main risk factors for development of SUI are
higher age, parity and obesity [3]. In white, non-Hispanic
women SUI is more common than in other ethnic groups
[4]. Other (chronic) comorbidities like physical inactivity
[5], diabetes, asthma and angina pectoris are also known to
negatively influence incontinence [3].
In this article an overview of the current therapeutical
options of this bothersome medical condition is given.
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Information is presented in a historical context, with per-
sonal experience from the authors. The data are supported
by recent literature found in PubMed, Cochrane and
Embase databases and the European Association of Urology
(EAU) [6] and International Consultation on Incontinence
(ICI) [7] guidelines on incontinence.
2. Diagnostics
When initiating treatment for female SUI, assessment of
the type of incontinence, either stress-, urge- (UUI), or
mixed urinary incontinence (MUI), is necessary first. In-
vestigations to distinguish between these types include
patient history, physical examination, voiding diaries, im-
aging techniques, pad weight testing and urodynamic
investigation.
2.1. Medical history taking
In medical history taking one should ask when incontinence
occurs. SUI occurs at moments of increased abdominal
pressure, during coughing, sneezing and/or straining. If
incontinence occurs after a feeling of urgency, without
abdominal pressure rise, urge-incontinence can be
assumed. By thoroughly asking for the symptoms, medical
history taking can for a large part distinguish between the
various forms of incontinence. In 20%e36% of patients MUI
is present, which consists of both forms of incontinence [8].
Because high-quality evidence is not available about the
ideal treatment of MUI, in these patients conservative
treatment of the most prominent form of incontinence is
recommended [8].
2.2. Physical examination
To support medical history taking, thorough physical ex-
amination is essential. During inspection of the female
genitals it is important to look at signs of vaginal atrophy,
pelvic organ prolapse and whether urethral hypermobility is
present or not.
Vaginal atrophy is a found in post-menopausal women
after lowering of estrogen levels. Local or systemic estro-
gen suppletion can help improve continence, as it will in-
crease the thickness of the urethral and vaginal mucosal
tissue, which in turn will lead to a better closing mecha-
nism. Treatment with estrogens might furthermore help to
improve the quality of the tissue. Although improved
quality and thickness of the vaginal wall suggests a more
easy procedure during pelvic surgery, no strong evidence
exists yet for advantages of pre-operative hormone
replacement therapy [9].
Assessment of pelvic organ prolapse is also an important
part of physical examination. It can be classified according
to several quantification-systems, for example the Pelvic
Organ Prolapse Qualification (POP-Q) score. The POP-Q
score assesses the position of the anterior and posterior
vaginal wall and the uterus compared to the hymenal ring
and quantifies this. A vaginal prolapse, especially from the
anterior wall, almost always leads to a decreased urethral
support, which in turn might lead to (stress) incontinence.
By supporting the urethra/anterior vaginal wall during
physical examination and performing a cough test simul-
taneously, one can mimic the effect after (surgical)
correction of this situation. Sometimes this effect can also
been seen after placing a pessary and these devices can be
used as a treatment for SUI in this way. Contradictory, in-
continence can develop after surgical correction of a pro-
lapse, because urethral kinking is made undone. The
straightened urethra is more vulnerable for developing SUI,
because the physiological mechanism of urethral closure is
impaired. Although prolapse and incontinence are closely
related to one another, we will not further discuss the
treatment of prolapse in this article.
In determining the type of stress urinary incontinence, it
can be useful to assess the degree of urethral mobility and
to diagnose intrinsic sphincter deficiency (ISD). Originally
these conditions, which both play a role in the pathogenesis
of SUI, were described as “type 1” and “type 3” inconti-
nence respectively. Based on John DeLancey’s hammock
theory [10], midurethral hypermobility causes SUI because
of a lack of support of the urethral sphincter. The urethral
sphincter is not capable to close the urethra during mo-
ments of high intra-abdominal pressure resulting in urinary
loss. This can be compared to a garden hose, that can easily
be compressed against a solid underground, but is hardly
compressible in loose sand. Intrinsic sphincter deficiency is,
as the name suggests, a failure of the sphincter mechanism
of the urethra itself. In these patients stress incontinence
can occur without the presence of urethral hypermobility.
Stress incontinence based on ISD is more severe and more
difficult to treat [11].
The clinical significance of distinguishing between these
different forms of SUI is subject of debate. In general, one
can state that in case of urethral hypermobility (with or
without ISD) treatment with a tension-free vaginal tape is
recommended. In case of ISD, one should consider rein-
forcing the urethral sphincter as well. This can be done
with a more compressive sling, an artificial sphincter or e in
case the patient is not fit or does not opt for surgery e
bulking agents.
Urethral hypermobility is mostly assessed by eyeball
observation. Classically it can also be diagnosed by per-
forming a Q-tip test, in which a cotton swab is placed in the
urethra. The patient is asked to strain, if the angle of the
cotton swab changes more than 30 from the original po-
sition, hypermobility is present. In clinical practice, it is not
commonly used.
Although the clinical significance of urodynamics in in-
dividual cases is disputable, urodynamic investigation can
give useful information about the type of incontinence.
First it can differentiate between SUI and UUI. Second, it
can diagnose ISD if urethral pressure profilometry (UPP) is
performed as part of the complete investigation. Generally,
an ISD is concluded if the maximal urethral closing pressure
(MUCP) is below 20 cmH2O (1.96 kPa), but the ranges are
wide. There is no consensus about whether the cut-off
point of the MUCP is a predictor for success of a possible
subsequent surgical procedure [12,13]. Several imaging
techniques are available to diagnose incontinence. The
most important are X-ray, ultrasound and magnetic reso-
nance imaging (MRI). All can be used to assess bladder neck
mobility and/or prolapse, but clinical usefulness for diag-
nosing SUI is minimal. Ultrasound, especially 4D-dynamic
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imaging, seems most feasible as it is cheap, readily avail-
able in an outpatient setting and does not have the disad-
vantage of ionizing radiation. Imaging is to be used in the
complicated cases, mainly to get a better understanding of
the anatomy.
Voiding diaries and pad weight testing are tools to
quantify and objectify urine loss, for the patient as well as
for the physician. Though these tests are as objective as
possible, inexpensive and non-invasive, less than 10% of
the urologists perform this test regularly [14]. The shorter
the test (1 h) the better the patient commitment, but
longer testing (for 48 or 72 h) gives more reproducible re-
sults [14].
Validated questionnaires can add extra information on
specific subjective aspects of incontinence, but should al-
ways be interpreted with care. A combination of subjective
and objective diagnostic tools gives the best insight in the
incontinence and can be a guidance for behavioral therapy
and the choice for eventual more invasive therapy.
3. Conservative management of stress urinary
incontinence
Conservative management is defined as any non-surgical
intervention for SUI. Whether or not pharmacological
treatment is included in this definition is debatable, but
this is not relevant considering the relatively small place for
medication in the curative treatment of SUI. According to
the EAU guidelines on incontinence [6], conservative ther-
apy is usually considered as initial treatment. It carries less
risks, is less invasive and often less costly than the more
invasive or surgical options. Conservative management can
consist of containment, a range of lifestyle interventions
and pelvic floor muscle training (PFMT), all with different
effectiveness and chance of success.
3.1. Lifestyle modifications
Obesity is significantly correlated to stress urinary inconti-
nence [15]. In a randomized trial under 338 stress inconti-
nent patients, women with 8.0% weight loss had a
significantly greater decrease in stress-incontinence epi-
sodes compared to the group with 1.6% weight loss after 6
months follow-up [16]. Interventions in lifestyle aimed at
weight reduction are therefore recommended (level of
evidence: 1B) [6].
Fluid and/or dietary management in general can be
beneficial, albeit mostly on urgency. Reducing the fluid
intake reduces the production of urine and with it, it re-
duces the amount of urine that can be lost because of in-
continence. One should however be careful to avoid
dehydration and take furthermore into account that no
clinical trial has confirmed the effect of fluid management
on SUI [17].
Dietary management other than aimed at weight
reduction can consist of reduction of caffeine and alcohol
intake. Constipation and smoking both have a positive in-
fluence on incontinence. Prevention and cessation of these
factors respectively can be beneficial for general health,
but there is no evidence that treating these factors inde-
pendently improves symptoms of incontinence [18].
3.2. Pelvic floor muscle training
The oldest form of PFMT are Kegel exercises, named after
the urologist Arnold Kegel, who first described these in 1948
[19]. They consist of sets of 8e12 contractions of the pelvic
floor that have to be sustained for about 10 s. These ex-
ercises require discipline and perseverance of the patients
as they should be repeated multiple times a day, for 4e5
months.
There has been ongoing discussion about the effect of
PFMT. Dumoulin et al. [20] systematically reviewed the
outcomes of 18 studies comparing PFMT versus no treat-
ment. They concluded that 56% was cured after PFMT, in
the untreated groups the cure rate was 6%. There is not
enough evidence to conclude a long-term effect in this
review, because only two articles gave limited information
on this topic. Most patients adhered well to the training
program for the duration of the studies. Little literature is
available about patient adherence after termination of a
study. In a Norwegian review two studies with 5 year
follow-up were found having an adherence percentage of
10%e70% [21].
There is furthermore no evidence of a benefit of
PFMT in addition to other conservative treatments, but
this conclusion was drawn based on a Cochrane review
of 13 relatively small studies, with a total of 1164 pa-
tients [22]. A randomized controlled trial (RCT) pub-
lished by Labrie et al. [23], in which 460 women were
randomized between physiotherapy and midurethral
sling surgery, shows that initial surgical treatment with
a midurethral sling, gives significantly higher objective
(59% vs. 77%) and subjective cure rates (53% vs. 85%)
after 1-year follow-up. Even after cross-over from the
physiotherapy-group to the surgery-group no additional
benefit was found of PFMT.
Superiority of PFMT over electrical stimulation and
bladder training has been shown for women with SUI. The
long-term effect is dependent on many factors, such as the
instructions/education that is given and the supervision
that can be provided. Despite the ongoing debate about its
effectiveness, it is still recommended (Grade A recom-
mendation) to start with this first-line therapy as it is non-
invasive, less costly and safe [6].
Biofeedback can help in training the muscles of the
pelvic floor, by giving the patient feedback on how the
exercise is performed. There are many “feedback” tech-
niques, from simple manual palpation, to vaginal cones of
different sizes that have to be kept in place, to more
expensive techniques based on electromyography (EMG).
Although it is helpful in some individual cases, addition of
biofeedback in any form to adequate PFMT was not
beneficial.
4. Minimally invasive treatment
4.1. Urethral bulking agents (UBAs)
UBAs or “injectables” are substances e either natural or
synthetic e that are injected periurethrally for the treat-
ment of stress urinary incontinence. Classically they have
been used in case of ISD. Their function is to increase
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urethral resistance by filling the periurethral space, and
possibly to increase urethral support [24].
Although a minimally invasive therapeutical option
should be attractive for this non-lethal medical condition,
bulking agents have up until now never become a great
success. There are several reasons for this fact. First, there
is a lower success rate compared to the other surgical
procedures [25]. Second, their efficacy in the long term is
limited [26], leading to reinjections and with it a reduced
cost-effectiveness. Finally, many UBAs have been associ-
ated with complications like allergic reactions, tissue
migration or formation of (sterile) abscesses [26].
The most widely used UBA was Contigen, which con-
sisted of bovine collagen. It was used for over 20 years with
dry-rates of about 30% (range 10%e83%) [27]. The product
has now been withdrawn from the market because of sup-
posed allergic reactions related to the procedure, but
several alternatives are currently available. The main dif-
ferences of the alternatives are the material used, the
intended injection location and the route and way of
application. No bulking agent has ever been proven to be
superior to the other [25], nor has the injection route
(either trans- or paraurethrally). The preferred position of
the bulking agent is at the level of the midurethra [28].
Most of the UBAs consist of a biodegradable carrier gel
which contains particles of some sort. The gel is degraded by
the body and scar tissue should be formed around the parti-
cles to create a permanent effect. Due to the degradation of
the gel however, the effect mostly diminishes over time.
Although improvement has been made, the ideal
bulking agent has not yet been found. It should be durable,
biocompatible, hypoallergenic, deformable, non-
immunogenic, with minimal inflammatory response and
should cause no migration [29]. Developments in this field
are continuously happening and especially in older patients
or patients that cannot undergo surgery, this can be a
valuable treatment option [30]. The latest EAU-guideline on
incontinence gives a grade A recommendation, based on
expert opinions, that bulking agents should not be offered
to women seeking a permanent cure for SUI [6].
5. Surgical interventions
After failure of conservative treatment(s), surgery should be
considered as a therapy for female stress urinary inconti-
nence. Traditionally, surgical treatment consisted of (open)
colposuspension following a MarshalleMarchettieKrantz
(MMK) or Burch procedure. In case of unsuccessful outcome
of these surgical technique, pubovaginal slings were used.
Many sling-procedures were performed, the earliest over
100 years ago; McGuire made improvements to the pro-
cedure, leading to increased popularity of this method from
the late 1970s.
With the introduction of the tension-free vaginal tape in
1996, followed by transobturator tape in 2001, surgical
treatment of SUI changed radically. With these relatively
simple and highly effective procedures, many women were
treated and the midurethral sling soon became the refer-
ence standard. As stated before, there are now even
studies indicating that in some patients surgical treatment
might be eligible as a primary treatment, even before
conservative management like PFMT [23].
Development did not stop after 2001. Driven by the
search for less complications and more minimally invasive
procedures, mini slings and single incision slings have been
developed. Furthermore, in the last years vaginal meshes
used for prolapse have developed a negative reputation
because of complications, which has reflected upon the
synthetic slings used for SUI. Whether justified or not, in
the past years there has been a shift to non-synthetic slings
and the number of revisions and removals of tapes has
increased almost three-fold in the USA [31]. Considering
these developments, the need for alternative treatments
remains topical.
5.1. Bladder neck colposuspension
The bladder neck colposuspension is designed to theoreti-
cally stabilize the urethra and reposition the bladder neck
and proximal urethra intra-abdominally. By restoring the
anatomy, pressure transmission from abdomen to urethra
during moments of increased intra-abdominal pressure can
be improved, leading to a better continence.
Several procedures and techniques are available. They
can be performed either open, laparoscopically or robot-
assisted. According to the ICI the medium to short-term
outcomes are comparable in terms of subjective outcome
(evidence level 2) [7], there is however a lack of long-term
data for laparoscopic techniques. Furthermore, the objec-
tive outcomes seemed to be inferior [32]. Absorbable or
non-absorbable sutures can both be used. The effect of the
procedure depends on the fibrosis resulting from it. Some
surgeons prefer absorbable sutures, to avoid early resorp-
tion, before enough fibrosis has occurred.
The MMK procedure was the first open colposuspension
described in 1949 [33]. It is a form of retropubic colposus-
pension, in which the urinary bladder and urethra are sus-
pended to the periosteum of the symphysis pubis. On both
sides of the urethra, three pairs of sutures are placed. The
sutures include tissue of the vaginal wall and the lateral
urethral wall, whilst sparing the mucosa of both. Although
successfully used for a long period of time in the treatment
of incontinence, complications did occur in about 20% of
the patients [34]. When placed in the wrong place, sutures
can damage the urethra, obstruct the bladder neck or they
can paradoxically open it, leading to persisting or wors-
ening SUI. The most serious complication observed in 0.9%e
3.2% of patients was osteitis pubis [34]. The morbidity
associated with the MMK procedure led to the development
of modifications of the procedure. As colposuspension ac-
cording to Burch has become the most performed proced-
ure, we will not discuss the success or failure rates here.
5.2. Burch colposuspension
Colposuspension according to Burch is a modification of the
MMK procedure, first described in 1961. In this procedure
the paravaginal fascia is not attached to the periost of the
pubic symphysis, but to Cooper’s ligament. This decreases
the risk of osteitis pubis.
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Both procedures have relatively high subjective and
objective cure rates. In a recent Cochrane review (2016)
about open retropubic colposuspension, which included 55
trials and 5417 patients, the cure rates were 70%e90%. The
effect tends to diminish from 85% to 90% after 1 year to
70% after 5-year follow-up [35]. Because of less compli-
cations, the Burch procedure has become the colposus-
pension of first choice and made the MMK procedure
obsolete. The MMK is therefore no longer recommended
for treatment of SUI by the 5th ICI consultation on incon-
tinence (2013) [7]. Together with pubovaginal slings, Burch
colposuspension is recommended (Grade A) by the latest
EAU-guidelines as a treatment in case midurethral slings
(MUS) are not eligible [6].
5.3. Pubovaginal slings (PVS)
Although used for over more than 100 years, PVS have never
been a treatment of first choice. They have classically been
used after failure of colposuspension or nowadays the
(synthetic) midurethral slings. There remains however an
indication for the use of this type of sling, especially
considering the negative publicity around complications of
synthetic material used for reconstruction of the female
pelvic floor. PVS can be used in case of intrinsic sphincter
deficiency, regardless whether urethral hypermobility is
present or not.
Many different techniques have been described, using
many different materials. Materials can be autologous,
allograft, xenograft or synthetic. The autologous materials
most commonly used as a graft are the rectus fascia or
fascia lata, of which a sling of >8 cm length and >2 cm
width is obtained. They are placed at the bladder neck, in
contrary to the newer generation of midurethral slings,
leading to urethral coaptation and a better continence.
Because the pubovaginal slings are usually applied more
firmly than the tension free alternatives, it is advisable to
teach patients clean intermittent catheterization before
surgery and to keep at least a space two fingers wide be-
tween the sutures of the sling and the fascia used. Further-
more one should perform urethrocystoscopy after the
procedure to check for possible bladder perforation [36].
Available literature shows a good effect of these pro-
cedures on incontinence. In a summary of the results of 23
studies with 2341 patients, a cure rate of 46%e97% was
found with autologous slings [37]. The sling made from
autologous rectus fascia seems to be an effective and du-
rable treatment. For many other PVS there is not enough
reliable data available to draw any conclusions about the
effect or feasibility of these procedures. In the latest
Cochrane review of 2011 [38], seven studies compared PVS
with Burch. Although evidence was in most cases poor with
a short follow-up, the cure rates were comparable for both
interventions. A systematic review and meta analysis from
Schimpf et al. [39] showed evidence that PVS has a superior
cure rate compared to Burch colposuspension based on 4
RCTs. This was not the case when PVS was compared to
(retropubic) MUS. Based on five lower-quality RCTs, an
inferior subjective cure with PVS is observed. In contrary, a
recent British multicentre RCT between tension free
vaginal tape (TVT), autologous fascia sling (AFS) and
xenograft sling in 201 women, concluded no differences in
long-term success rates between AFS and TVT. There was
however some evidence that the long-term dry-rates of the
AFS may be superior. When comparing the outcomes of MUS
and PVS one should of course take into account that the PVS
procedure is more invasive because of harvesting of the
graft material and more time consuming.
The main complications of the PVS are erosion and
extrusion to urethra and vagina and de novo urgency and
urge incontinence. With autologous or biomaterial grafts
the risk for erosions is considerably lower than with syn-
thetic slings.
In recent years there has been an increase in PVS pro-
cedures performed, especially in the USA [31]. Due to the
non-inferior clinical outcomes compared to synthetic slings
and Burch and the fact that autologous material is
preferred above synthetic, the pubovaginal slings have an
ever relevant place in the treatment of female stress uri-
nary incontinence.
5.4. Midurethral slings
5.4.1. Retropubic tapes
Introduced in 1996, this first version of a midurethral
tape has become a revolutionary success in the treatment
of female SUI. Based on the integral theory posed by
Petros and Ulmsten [40], the tape is positioned on the
middle, high pressure part of the urethra, mimicking the
function of the pubourethral ligament. As the name
suggests, the arms of the slings are positioned in the
retropubic space. The majority of tapes consist of poly-
propylene, a material that shows less erosion than
previously used materials like polyethylene or polytetra-
fluoroethylene. The sling should furthermore be macro-
porous, with a pore size of >75 mm.
The procedure is less invasive than colposuspension or a
pubovaginal sling. Operating time is shorter, recovery time
is shorter and the outcome is as good as the more invasive
procedures. In a systematic review by Ford et al. [41], 81
trials with 12 113 women were included, who all received a
sling treatment for SUI or MUI. The short term subjective
success rates of this procedure lie between 71% and 97%.
Long-term (>5 years) results based on four articles (714
patients) in this review were lower with 51%e88%. In a
French retrospective study in 463 women with a mean
follow-up of 71 months 74% reported subjective cure, 12%
was improved and 14% had treatment failure [42].
Complication levels after the procedure are acceptable.
In a retrospective study after the complications of TVT by
Kristensen et al. [43], 778 procedures were analyzed. The
most common intra-operative complication was bladder
perforation (6.6%). Postoperatively voiding difficulty (56%)
and urinary retention (16.6%) were most commonly seen.
5.4.2. Transobturator tapes
In an attempt to decrease the risk of complications asso-
ciated with the retropubic tape (bladder perforation,
vascular injury), the transobturator tape was introduced in
the beginning of this millennium. It is, like the retropubic
tape, implanted tension-free at the level of the mid-
urethra. The arms of the sling are however positioned in the
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obturator foramen, puncturing the adductor muscles. It can
be introduced outside-in (i.e., introduction through an
incision in the groin), or inside-out (i.e., introduction
through vaginal incision and exit through groin). None of
these techniques is superior to the other [41,44].
The subjective cure rate of the combined transobturator
procedures is 62%e98% after a follow-up of 1 year. The
long-term effect (>5 years) lies in the range of 43%e92%
[41]. In a multicentre prospective study after tension free
vaginal tape e obturator (TVT-O) in 160 women, a follow-up
of 10 years was reached [44]. In this study, there was a
subjective cure rate of 97% and the objective cure rate was
92%. This indicates that satisfying long-term results can be
achieved with this procedure.
Compared to more invasive procedures like Burch col-
posuspension and pubovaginal slings, the risk of complica-
tions with MUS is low. However, especially now studies with
larger groups of patients with a longer follow-up are being
published, there are side effects of these procedures. The
complications observed with retropubic a´nd transobturator
tapes together are: de novo urge and urge-incontinence
(8%), postoperative voiding difficulties (6%), chronic pain
(5%), vaginal erosion (2%) and bladder perforation (3%) [41].
The clinical effectiveness of both retropubic and trans-
obturator is comparable, as are the route of introduction
(inside out or outside in). There is a difference in types of
complications. Considering the effectiveness and safety of
both procedures, there is no strong indication for either one
of the slings or routes. Groin pain and sexual dysfunction
are more common after the transobturator approach [45],
bladder perforation tends to occur more often using the
retropubic route as were post-operative voiding difficulties.
It is recommended to discuss the side-effects of both
therapies with the patient and to choose a type of sling
based on patient preference. Also in redo cases the retro-
pubic route is recommended by most guidelines. Studies
show that this can also be highly effective [46].
5.4.3. Single incision mini slings (SIMS)
The SIMS are a shorter version of the conventional mid-
urethral slings described earlier. The first mini sling was
introduced in 2006 and since that time many different
products were marketed. They are all developed based on
the theory that they are shorter and require no blind pas-
sage of a needle through the obturator foramen or the
retropubic area. Furthermore there is need for only one
vaginal incision in the midline, no other skin incisions are
necessary. These properties should lead to a reduced risk of
damaging anatomical structures and the morbidity associ-
ated with this damage. The main differences between the
mini slings are the lengths and the anchoring systems.
Usually the mini slings are anchored to the pubocervical
fascia.
After introduction the objective and subjective cure of
SIMS at the mid- and long-term first appeared to be inferior
to the MUS. This even led to withdrawal of the widely
investigated TVT-Secur. Recent reviews do however
conclude that there is no significant difference in
(midterm) cure for SIMS compared to MUS [47]. The dura-
tion of the operation is usually shorter, the recovery is
faster and postoperative pain is less, as are intraoperative
complications like erosions and peroperative blood loss,
according to the EAU guidelines (level of evidence: 1B) [6].
One of the SIMS with a different approach to placement
is the SIMS-Ajust, which is used since 2009. One anchor of
the arms of this midurethral sling makes intraoperative
adjustment of the tension of the tape possible. After
adequate tensioning the tape is secured. In a meta-analysis
from 2015, Zhang et al. [48] found five RCTs with a total of
678 patients comparing SIMS-Ajust with TVT-O and TOT.
They reported, based on these studies, that there was no
significant difference in subjective (RR Z 0.95, 95%CI:
0.871.04, p > 0.05) or objective (RR Z 0.97, 95%CI:
0.901.05, p > 0.05) cure rates. The complication rates are
also not significantly different, making a shorter operating
time the main advantage of this procedure. The long term
outcome with the SIMS-Ajust is still unknown.
The latest Cochrane review concludes that there is not
enough evidence to make a reliable comparison between
SIMS and MUS [49]. More RCTs are necessary, data from one
study can not be used to draw conclusions about other
products because of different lengths and anchoring tech-
niques. Even if future research shows lower efficacy this does
not mean that there is no place for SIMS in the treatment of
female SUI. Research shows that if postoperative pain can be
prevented by a less invasive procedure, patients are willing
to accept slightly lower cure rates [50].
5.5. Artificial urinary sphincter (AUS)
The AUS was first developed about 40 years ago. It has
gradually evolved to the implantable medical device we
know today, that consists of three main items. There is an
(mostly abdominal) pressure regulating balloon, a cuff that
is placed around the urethra, and a little pump in the labia
that can be switched to inflate the cuff. The different parts
consist of a silicone elastomer and are connected through a
liquid-filled system. By mechanically closing of the urethra,
sphincter function is simulated and stress urinary inconti-
nence can be treated.
It is used mostly in case of intrinsic sphincter deficiency
and after failure of other less invasive procedures. In male
post-prostatectomy, sphincter implantation is much more
common. It is estimated that of all the AUS implanted, only
1% is implanted in women. The procedure can be performed
transvaginally, retropubically/trans-abdominally and open
or laparoscopically. No randomized controlled trials have
been performed after the ideal route of transplantation.
The retropubic route is however considered the most
eligible, as the transvaginal route is associated with higher
morbidity and infection rates [51]. Some recent research
shows that robot assisted laparoscopic implantation
possibly leads to less complications [52].
The overall rates of cure or improvement are 76%e89%.
In recent years more data about the long-term effect are
being published. After 20 years 11 out of 34 women still had
successful outcomes [53]. In the same group of patients 26
out of 34 patients had the implant still in place.
Explantation can be necessary in case of device failure
or severe complications. Device failure was reported to be
as high as 15% [54]. Complications include among others
erosion (15%) and infection (4.8%) [55]. Urethral atrophy
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occurs frequently, but for female patients there is a lack of
data on the incidence of this complication [55].
Because of the risk of complications and device-failure,
an AUS is mostly a therapy of last resort in women.
Furthermore implantation is reserved for specialized cen-
ters. If it is nevertheless considered, patients should be
informed about the risk of complications. In case of suc-
cessful treatment, the effect can be durable for years.
Lifelong follow-up is often necessary.
6. Conclusion
The widely prevalent medical condition of stress urinary
incontinence has been treated over a century in many
different ways. The first non-conservative treatments were
large open colposuspensions, later followed by pubovaginal
slings. Both techniques were refined to acceptable treat-
ments with a good effect on incontinence, albeit with side
effects.
Treatment of SUI changed radically after introduction of
the significantly less invasive midurethral synthetic slings.
Although also these procedures are continuously being
refined by for example development of the single incision
mini slings, the MUS is still the reference standard for
treatment of uncomplicated SUI. Single incision mini slings
still have to prove their e especially long-term e efficacy.
In the last years there is more attention for the draw-
backs of the synthetic midurethral slings and the position of
the older surgical techniques is reconsidered. This led to an
increase in colposuspensions performed and autologous
pubovaginal slings placed. These techniques are recom-
mended when slings are not eligible. The artificial urinary
sphincter can be a therapy of last resort, that is very rarely
placed, mainly due to complications and device failure.
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